Area of research
Reproductive Medicine · Oncology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments, and BRCA gene mutations in cancer.
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
A nurse- and peer-led psycho-educational intervention to support women with gynaecological cancers receiving curative radiotherapy: The PeNTAGOn randomised controlled trial – ANZGOG 1102
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
The molecular origin and taxonomy of mucinous ovarian carcinoma
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer
Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer
Radiation-induced vaginal stenosis: current perspectives
Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer. A randomized clinical trial
UWA Profiles and Research Repository (University of Western Australia) 2017cited by 53position: middle
Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling
Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer